You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Chromium Connect, designed for pharma workflows and other high-volume customers, is one of several products coming out of 10x's R&D pipeline.
In its first quarter as a public company, the single-cell analysis firm reported $61.2 million in total revenues, beating Wall Street expectations.
The collaborators are developing a sample prep solution for the Mission Bio Tapestri platform and are working on a hematology-focused panel.
The scientists aim to use single-cell analysis to investigate the role of variation in a gene called ID3 in vascular smooth muscle cells.
MGI hopes to ship the sequencer, one of several products it unveiled at the International Conference on Genomics, to early-access partners in early 2020.
The project is part of the Human Cell Atlas, an international effort to build reference maps of all human cell types using single-cell analysis.
10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
The researchers molecularly characterized cells found in cirrhotic tissue that express genes involved in pro-fibrogenic pathways that could be targeted by drugs.
Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.